Monoclonal antibody recognizing sialylated sugar chains
US9796785B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | May 2, 2014 |
| Grant date | Oct 24, 2017 |
| Priority date | — |
| Expiry date | May 2, 2034 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2440/38
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The purpose of the present invention is to provide a novel monoclonal antibody having high affinity and that strictly recognizes, as a sugar chain epitope, only a “Siaα2,6Galβ1,4GlcNAc (6′-Sialyl-LacNAc): CDw75” sugar chain structure, being a molecular target for diagnosis of the malignancy of tumors. An anti-CDw75 monoclonal antibody is provided that recognizes “CDw75” sugar chain structures but does not recognize similar sugar chain structures indicated by “Galβ1,4GlcNAc”, “Siaα2,3Galβ1,4GlcNAc”, or “Siaα2,6Galβ1,4Glc”, by using a glycolipid antigen bonding a carrier lipid compound “HOCH2CH(NH—CO—(CH2)22—CH3)—(CH2)9—CH3 (C12L)” developed by the inventors to a “CDw75” sugar chain. The obtained anti-CDw75 monoclonal antibody is an excellent detection drug for B-cell lymphoma, gastric cancer, or colorectal cancer, an excellent diagnostic agent for tumor malignancy, etc., an excellent treatment agent for B-cell lymphoma, gastric cancer, or colorectal cancer, and an excellent prevention/treatment drug for influenza.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.